• Minoryx
    Minoryx
    Home
    Our Company
    Who we areManagement teamBoard of directorsScientific advisory boardFunding
    Our Science
    OverviewAdrenoleukodystrophyFriedreich's ataxia
    Our Programs
    OverviewLeriglitazone
    Clinical Studies
    Clinical Studies ADVANCEFRAMESNEXUSResourcesExpanded Access Policy
    Media
    Careers
    Follow us
    Contact
    Overview
    Home Our Programs Overview
  • Leriglitazone
    Clinical phase
    Indication
    Preclinical
    Phase 1
    Proof of Concept
    Registration Enabling
    NDA/MAA
    X-ALD+
    Friedreich's Ataxia+
    Other CNS Diseases+
    AMN
    cALD

    Minoryx’s lead program is a selective, differentiated PPAR gamma agonist (leriglitazone) being developed for the treatment of X-linked Adrenoleukodystrophy (X-ALD); it has the potential to treat both the severe cerebral form of ALD (cALD) and the milder form, adrenomyeloneuropathy (AMN), as well as other orphan CNS diseases, such as Friedreich's Ataxia (FRDA).

    Leriglitazone is currently being evaluated in a registration enabling clinical trial (ADVANCE) in adult AMN patients in EU and US and a proof of concept trial (FRAMES) in patients with FRDA. Recruitment for both studies has been completed and results for both studies are expected by end 2020. In addition, recruitment of the registration enabling study in patients with cerebral Adrenoleukodystrophy (cALD) in EU has started.

    More info
    Focus
    Mechanism of Action in X-ALD
    Read more
    Focus
    Mechanism of Action in FRDA
    Read more
  • Contact
    Headquarters
    https://www.minoryx.com/content/imgs/mail/logo.png
    Av. Ernest Lluch 32 - TCM3
    08302 Mataró
    (Barcelona) Spain
    info@minoryx.com 0034935441466+34 93 544 14 66
    Belgian R&D Site
    https://www.minoryx.com/content/imgs/mail/logo.png
    Rue Auguste Piccard 48, I - Tech Incubator
    6041 Gosselies
    (Charleroi) Belgium
    info@minoryx.com 003278700162+32 787 00 162
    Contact
    Follow us
    Legal Notice Privacy Policy Cookies Policy
    by eMascaró